IMMX Stock Forecast: Immix Biopharma, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$6.96
−1.14% on the day

The median 12-month analyst price target for Immix Biopharma, Inc. is $23. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 38 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$590.0M
Ticker Nerd rank
38/ 100
Median analyst target
$23
Analysts covering
7
Revenue$0.0
Operating income−$12.5M
Net income−$11.6M
Free cash flow−$11.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−11.2%
1M
−21.9%
YTD
+33.1%
1Y
+73.1%
From 52W high
−51.9%
From 52W low
+75.3%
$4
$14
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Immix Biopharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
38/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
79
Quality
69
Value
54
Revisions
52
Volatility
50
Issuance
26
Growth
21
Accruals
17

Momentum (79): The shares have been drifting up relative to others.

Accruals (17): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

IMMX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on IMMX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15$20$25$30Jan 26Apr 26Jul 26Oct 26IMMXHigh $30Median $23Low $17

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
7
Buy
0
Hold
0
Sell
$17
Low
$23
Median
$30
High
Recent analyst actionsNewest first

Of the 20 most recent actions, 5 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
18 Nov 2026MizuhoMaintainsOutperform$23 → $22
18 Nov 2026Morgan StanleyMaintainsOverweight$20 → $21
16 Nov 2026HC Wainwright & Co.MaintainsBuy$25 → $27
29 Sept 2026NeedhamMaintainsBuy$21 → $30
15 Sept 2026MizuhoMaintainsOutperform$15 → $26
11 Aug 2026Morgan StanleyMaintainsOverweight$20 → $19
10 Aug 2026HC Wainwright & Co.MaintainsBuy$20 → $25
22 July 2026NeedhamInitiatesBuy$21
18 June 2026B of A SecuritiesInitiatesBuy$27
17 June 2026LifeSci CapitalInitiatesOutperform—
22 May 2026HC Wainwright & Co.MaintainsBuy—
30 Mar 2026HC Wainwright & Co.ReiteratesBuy—
30 Mar 2026MizuhoMaintainsOutperform—
27 Mar 2026CitizensReiteratesMarket Outperform—
27 Mar 2026HC Wainwright & Co.MaintainsBuy—
25 Mar 2026Morgan StanleyInitiatesOverweight—
9 Mar 2026CitizensInitiatesMarket Outperform—
9 Feb 2026MizuhoInitiatesOutperform—
9 Dec 2025HC Wainwright & Co.MaintainsBuy—
12 Sept 2025HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for IMMX.

Market Radar

This page is one stock. Monday covers all of them.

IMMX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

IMMX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Immix Biopharma, Inc. returned +73.1% against +6.9% for the S&P 500, dividends included.

IMMX vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250300350Jan 26Apr 26Jul 26Oct 26IMMXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

IMMX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
2
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
1.8×

Cheaper than 48% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−26.9%

Higher than 29% of US stocks

Return on assets
−17.1%

Higher than 21% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Immix Biopharma, Inc. has a market value of $590.0M and an enterprise value of $254.7M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$39.9M.

  • Free cash flow in the twelve months to 30 June 2026: −$39.1M.

  • Shares outstanding: 71.2M.

  • Immix Biopharma, Inc. employs 21 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

IMMX and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
IMMXImmix Biopharma, Inc.$590.0M38
CGEMCullinan Therapeutics, Inc.$577.1M67
ENTXEntera Bio Ltd.$572.2M38
QUITAchieve Life Sciences, Inc.$572.1M44
ANNXAnnexon, Inc.$587.7M39
FDMT4D Molecular Therapeutics, Inc.$565.1M50
GERNGeron Corp.$557.7M71

Take a look at IMMX’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Immix Biopharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about IMMX

What is the IMMX stock price forecast for 2026-2027?

The median 12-month analyst price target for Immix Biopharma, Inc. is $23, with estimates ranging from $17 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is IMMX stock a buy right now?

Of the 7 analysts covering Immix Biopharma, Inc., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Immix Biopharma, Inc. 38 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank IMMX?

As at 21 Nov 2026, Immix Biopharma, Inc. ranks 38 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Momentum (79 of 100).

Will IMMX stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts is $23, and Ticker Nerd's factor model ranks Immix Biopharma, Inc. 38 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the IMMX stock forecast for 2030?

No analyst covering Immix Biopharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IMMX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $17 to $30 over the next 12 months.

How has IMMX stock performed over the past year?

Immix Biopharma, Inc. returned +73.1% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Immix Biopharma, Inc. do?

Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies and tissue-specific therapeutics for serious diseases, with an emphasis on AL amyloidosis, immune-mediated conditions, and select cancers. Immix Biopharma’s current pipeline is led by NXC-201, a BCMA-targeted CAR-T cell therapy being evaluated for AL amyloidosis and related plasma-cell disorders, and IMX-110, a tissue-specific therapeutic studied in solid tumors.

Company

About Immix Biopharma, Inc.

Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies and tissue-specific therapeutics for serious diseases, with an emphasis on AL amyloidosis, immune-mediated conditions, and select cancers. Immix Biopharma’s current pipeline is led by NXC-201, a BCMA-targeted CAR-T cell therapy being evaluated for AL amyloidosis and related plasma-cell disorders, and IMX-110, a tissue-specific therapeutic studied in solid tumors. The company also works on immune-dysregulated and inflammatory diseases through its proprietary therapeutic platforms. Immix Biopharma operates in the biotechnology sector, where its role is centered on advancing investigational treatments designed to address high-unmet-need conditions through cell therapy and precision drug delivery approaches. Founded in 2012 and headquartered in Los Angeles, California, Immix Biopharma is positioned as a development-stage company focused on translating specialized oncology and immunology research into clinical programs.

CEO Dr. Ilya Rachman M.B.A., M.D., Ph.D. · 21 employees · United States · https://www.immixbio.com